CD8A and neoplasm: All the mMCP-counter studies are consistent with our above TIL pharmacodynamic results which is consistent with our MOA hypothesis per the above studies: CD4+-TILs (Treg) plays key role in suppression of anti-tumor immunity (CD8+ TCTL) in MC38 tumors and CD4+-Teff TILs plays key role in anti-tumor immunity in Hepa1-6 tumors.